Bedrijfsoverzicht
TriSalus Life Sciences, Inc. is primarily engaged in the research, development, and commercialization of a proprietary drug delivery technology platform alongside immuno-oncology therapeutics designed to enhance patient outcomes for difficult-to-treat liver and pancreatic cancers within the United States. The company operates within the broader Healthcare sector, specifically focusing on the Medical Devices industry, a segment characterized by high regulatory standards and a focus on innovative therapeutic solutions. As of the latest data, the entity maintains a market capitalization of $259.17M, generates an annual revenue of $45.15M, and employs a workforce of 102 individuals. These valuation and revenue figures indicate that TriSalus Life Sciences, Inc. is a small-cap entity with significant growth potential, yet its financial profile reflects the capital-intensive nature of developing medical devices and oncology treatments where revenue generation often lags behind substantial research expenditures. The disparity between its $259.17M market cap and its $45.15M revenue suggests that the market prices the stock based on future expectations of the drug delivery platform's success rather than current operational cash flows, a common dynamic for companies in the early commercialization phases of the Medical Devices industry.
Financiële gezondheid
The company reported a revenue of $45.15M over the trailing twelve months, yet it recorded a net income of $-69,690,000 and an EBITDA of $-26,320,000, revealing a cost structure where operating expenses significantly outweigh earnings before interest and taxes. This substantial gap between the positive revenue and the negative net income highlights the heavy burn rate associated with research and development activities inherent to the Medical Devices industry. The free cash flow stands at $-8,759,250, which indicates that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity for debt repayment or shareholder returns. TriSalus Life Sciences, Inc. holds $20.44M in cash against a total debt obligation of $34.44M, resulting in a debt-to-equity ratio of N/A due to the negative equity position implied by the financial metrics. Despite the debt exceeding cash on hand, the current ratio of 2.80 suggests that the company possesses sufficient current assets relative to its current liabilities to meet short-term obligations without immediate distress. The return on equity is N/A, while the return on assets is -56.8%, metrics that collectively reveal that management is currently deploying capital in a manner that reduces overall asset efficiency rather than generating immediate returns, a typical phase for biotechnology firms scaling up their product portfolios. The gross margin of 84.6% demonstrates strong pricing power or low cost of goods sold for the medical devices, contrasting sharply with the operating margin of -24.8% and profit margin of -86.9%, which indicate that general and administrative expenses, particularly R&D, are eroding profitability before interest and taxes.
Waarderingsbeoordeling
The trailing P/E ratio is N/A, while the forward P/E is -16.88, implying that the market does not expect immediate earnings recovery but rather anticipates a significant turnaround or restructuring before positive earnings are realized. The price-to-book ratio is -6.23, a metric that is unusual for public companies and indicates that the market values the company at a significant discount to its book value, potentially reflecting concerns over the solvency or the intangible nature of its assets in the Medical Devices industry. Alternative valuation metrics such as the price-to-sales ratio of 5.74 and the EV/EBITDA of -10.36 suggest that the stock is priced based on revenue multiples rather than earnings, a standard practice for loss-making growth companies where revenue expansion is the primary valuation driver. The 52-week high is $7.95 and the 52-week low is $3.42, placing the current trading environment within a volatile range that reflects the speculative nature of investing in a company with negative earnings and a forward P/E of -16.88. The beta value of 0.54 indicates that the stock's price volatility is less than 54% of the broader market, suggesting that TriSalus Life Sciences, Inc. moves with less sensitivity to general market swings compared to large-cap healthcare peers. This lower beta, combined with a market cap of $259.17M, positions the stock as a moderate-risk instrument for investors specifically seeking exposure to the immuno-oncology sub-sector, although the negative financial returns present a distinct risk profile.
Growth & Income
TriSalus Life Sciences, Inc. achieved a revenue growth rate of 59.8% year-over-year, whereas the earnings growth rate is N/A due to the company's current losses, implying that revenue expansion is the sole engine of growth while profitability remains elusive. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all available earnings and cash flow are being reinvested into research, development, and the commercialization of the drug delivery technology platform. The absence of a dividend payout ratio confirms that the company prioritizes funding its immuno-oncology therapeutics projects and expanding its market presence over returning capital to shareholders. Overall, the growth and income profile of TriSalus Life Sciences, Inc. is characterized by rapid top-line expansion coupled with persistent negative earnings and no income distribution, a trajectory typical for biotechnology firms in the development stage that rely on external capital or cash reserves to sustain operations until product approvals are secured.